[go: up one dir, main page]

DK0722344T3 - Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel - Google Patents

Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel

Info

Publication number
DK0722344T3
DK0722344T3 DK94928864T DK94928864T DK0722344T3 DK 0722344 T3 DK0722344 T3 DK 0722344T3 DK 94928864 T DK94928864 T DK 94928864T DK 94928864 T DK94928864 T DK 94928864T DK 0722344 T3 DK0722344 T3 DK 0722344T3
Authority
DK
Denmark
Prior art keywords
polyether
pct
agent
sec
solution
Prior art date
Application number
DK94928864T
Other languages
English (en)
Inventor
Johann Eibl
Friedrich Dorner
Noel Barrett
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4434538A external-priority patent/DE4434538C2/de
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0722344T3 publication Critical patent/DK0722344T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088Liquid substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827Proteins from mammals or birds
    • Y10S530/829Blood
    • Y10S530/83Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK94928864T 1993-10-06 1994-10-06 Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel DK0722344T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4334087 1993-10-06
DE4434538A DE4434538C2 (de) 1993-10-06 1994-09-27 Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
PCT/EP1994/003298 WO1995009657A1 (de) 1993-10-06 1994-10-06 Verfahren zur virusinaktivierung in gegenwart von polyalkylenglykol sowie die dabei erhaltene pharmazeutische präparation

Publications (1)

Publication Number Publication Date
DK0722344T3 true DK0722344T3 (da) 2002-03-18

Family

ID=25930216

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94928864T DK0722344T3 (da) 1993-10-06 1994-10-06 Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel

Country Status (12)

Country Link
US (1) US5770199A (da)
EP (1) EP0722344B1 (da)
JP (1) JPH09503218A (da)
AT (1) ATE211927T1 (da)
CA (1) CA2173625A1 (da)
CZ (1) CZ95296A3 (da)
DK (1) DK0722344T3 (da)
ES (1) ES2173923T3 (da)
FI (1) FI961536A0 (da)
HR (1) HRP940645A2 (da)
HU (1) HU218490B (da)
WO (1) WO1995009657A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301921A1 (en) * 1997-08-20 1999-02-25 John Graham Goddard Compositions containing polyethylene glycol and uses thereof
US6078119A (en) * 1997-11-26 2000-06-20 Ebara Corporation Bearingless rotary machine
AUPP276098A0 (en) * 1998-04-01 1998-04-30 Nokuta Pty Ltd A method for treating gelatine
SI1151007T1 (sl) * 1999-02-12 2006-10-31 Baxter Ag Postopek za pripravo pripravka na osnovi fibrinogena in fibronektina in proteinski sestavki, ki jihlahko dobimo po tem postopku
DE19923027C2 (de) * 1999-05-19 2002-09-19 Aventis Behring Gmbh Verfahren zur Inaktivierung von Viren
US6699465B2 (en) 2001-05-18 2004-03-02 Albany Medical College Covalent attachment of polymer to cell to prevent virus bonding to receptor
US7452539B2 (en) * 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
SI1476201T1 (sl) 2002-02-19 2009-06-30 Resolution Chemicals Ltd Sterilizacija steroidov, osnovana na topilu
US8450378B2 (en) * 2006-02-09 2013-05-28 Gojo Industries, Inc. Antiviral method
US8119115B2 (en) * 2006-02-09 2012-02-21 Gojo Industries, Inc. Antiviral method
US9629361B2 (en) * 2006-02-09 2017-04-25 Gojo Industries, Inc. Composition and method for pre-surgical skin disinfection
EP2522755B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
KR100900013B1 (ko) 2007-12-04 2009-05-29 씨제이제일제당 (주) 유체로부터 재조합 인간 에리스로포이에틴을 정제하는 방법
JP5730211B2 (ja) * 2008-11-20 2015-06-03 バイオジェン アイデック エムエー インコーポレイティドBiogen Idec Inc. ウイルスのアルギニン不活化
ATE543384T1 (de) * 2008-12-12 2012-02-15 Oro Clean Chemie Ag Viruzides desinfektionsmittel
MX369444B (es) 2012-02-29 2019-11-08 Baxalta Inc REMIELINIZACION DE NERVIOS PERIFERICOS ESTIMULADA POR IgG.
KR102238133B1 (ko) * 2013-11-15 2021-04-09 제넨테크, 인크. 환경-친화적 세제를 사용한 바이러스 불활성화 방법
ES2991988T3 (es) * 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
WO2022029674A1 (en) * 2020-08-05 2022-02-10 Takeda Pharmaceutical Company Limited Methods for preparing and purifying environmentally compatible detergents

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2232820A (en) * 1938-08-19 1941-02-25 Wood John Mfg Co Inc Switch and computer control for fluid dispensing pumps
US2303432A (en) * 1939-10-20 1942-12-01 Atlas Powder Co Shortening
US2232821A (en) * 1940-04-09 1941-02-25 Andrew A Barna Antiskidding device
US2380166A (en) * 1941-05-27 1945-07-10 Atlas Powder Co Emulsions
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
CA1101332A (fr) * 1976-01-30 1981-05-19 Edward Shanbrom Procedes simplifies pour la preparation de concentres de facteur viii de tres grande purete
US4412985A (en) * 1980-10-06 1983-11-01 Edward Shanbrom Depyrogenation process
DE3173208D1 (en) * 1980-10-06 1986-01-23 Edward Shanbrom Method of reducing undesirable activities of biological and pharmaceutical products
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US5055557A (en) * 1983-03-04 1991-10-08 Scripps Clinic & Research Foundation Ultrapurification of factor IX and other vitamin K-dependent proteins
DE3473407D1 (en) * 1983-05-02 1988-09-22 Immuno Ag Method of inactivating pathogens
US4727027A (en) * 1983-05-02 1988-02-23 Diamond Scientific Co. Photochemical decontamination treatment of whole blood or blood components
US4764369A (en) * 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
JPH0662436B2 (ja) * 1986-05-19 1994-08-17 株式会社ミドリ十字 静注用免疫グロブリン製剤の製造方法
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
CA2006684C (en) * 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
ES2042138T3 (es) * 1989-05-24 1993-12-01 Miles Inc. Filtracion en gel del factor viii tratado termicamente.
EP0431129B1 (en) * 1989-06-15 1996-05-29 Rorer International (Overseas) Inc. Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
JP3145696B2 (ja) * 1990-10-05 2001-03-12 日本ケミカルリサーチ株式会社 分泌型免疫グロブリンa製剤の製造法
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Also Published As

Publication number Publication date
FI961536A (fi) 1996-04-04
ATE211927T1 (de) 2002-02-15
CA2173625A1 (en) 1995-04-13
EP0722344B1 (de) 2002-01-16
HU218490B (hu) 2000-09-28
WO1995009657A1 (de) 1995-04-13
ES2173923T3 (es) 2002-11-01
HUT75310A (en) 1997-05-28
FI961536A0 (fi) 1996-04-04
JPH09503218A (ja) 1997-03-31
CZ95296A3 (en) 1996-09-11
US5770199A (en) 1998-06-23
HU9600906D0 (en) 1996-05-28
HRP940645A2 (en) 1996-12-31
EP0722344A1 (de) 1996-07-24

Similar Documents

Publication Publication Date Title
DK0722344T3 (da) Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
CA2034489A1 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
BG100455A (en) Hiv protease inhibitors
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
DK1299130T3 (da) Fremgangsmåde til behandling og forebyggelse af smitsomme sygdomme
DE69410254D1 (de) Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
NO962017D0 (no) 5,6-Dihydropyron - derivater som protease-inhibitorer og antivirus-midler
DE60009146D1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
NO962018L (no) 5,6-dihydropyron-derivater som protease-inhibitorer og antivirus-midler
ATE179164T1 (de) Hiv-proteaseinhibitoren
DE69909747D1 (de) Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen
CA2100066A1 (en) Michellamines useful as antiviral agents, composition and method of treatment
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
FR2735984B1 (fr) Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
DE69413952D1 (de) Extraktion von zellgebundenem protein von bordetella
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE174507T1 (de) Verwendung eines benzimidazolwurmmittels zur behandlung von mikrosporeninfektionen
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DE69231465D1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE165508T1 (de) Verwendung von 2-methylamino-2-phenylcyclohexanon zur behandlung von infektionen und zur immunmodulation